Loughborough, England – July 21, 2022 (GlobeNewswire) – Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...
Loughborough, England, June 30, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...
Loughborough, England, May 23, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD), a medical technology company focused on...
Loughborough, England, Feb. 28, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...
Loughborough, England, Feb. 14, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical...
Loughborough, England – January 10, 2022 (GlobeNewswire) – Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology...
Loughborough, England, Jan. 07, 2022 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on...
Sales in UK expected to be followed by launches across major EU territories in 2022 Loughborough, England, Dec. 07,...
Loughborough, England, Nov. 03, 2021 (GLOBE NEWSWIRE) — Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on developing...
MiBoKo, a noninvasive glucose sensor utilizing AI mobile application, addresses a substantial multibillion-dollar market opportunity in healthcare LOUGHBOROUGH, England,...